A previous study revealed that tumor multiplicity and incidence of skin tumors in DT-induced two-stage skin carcinogenesis accelerated by BRAF inhibitor was decreased when a COX-2 inhibitor celecoxib was orally administrated [29]. This evidence concerns the gene BRAF and skin neoplasm.